Aardvark Therapeutics Inc
AARD
Company Profile
Business description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Contact
4370 La Jolla Village Drive
Suite 1050
San DiegoCA92122
USAT: +1 858 225-7696
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Chart of the week: Why small caps could shine bright in 2025
The Chart of the Week is a reason why small caps may shine bright in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,601.70 | 97.40 | -1.12% |
| CAC 40 | 8,122.58 | 12.04 | 0.15% |
| DAX 40 | 22,314.65 | 118.98 | -0.53% |
| Dow JONES (US) | 44,176.65 | 450.94 | -1.01% |
| FTSE 100 | 8,662.97 | 49.56 | -0.57% |
| HKSE | 22,576.98 | 367.26 | -1.60% |
| NASDAQ | 19,962.36 | 93.89 | -0.47% |
| Nikkei 225 | 38,678.04 | 486.57 | -1.24% |
| NZX 50 Index | 12,785.90 | 94.46 | -0.73% |
| S&P 500 | 6,117.52 | 26.63 | -0.43% |
| S&P/ASX 200 | 8,322.80 | 96.40 | -1.15% |
| SSE Composite Index | 3,350.78 | 0.76 | -0.02% |